BiomOrgan Limited is a Hong Kong-based life science company founded in 2021 and strategically located at the Hong Kong Science and Technology Parks (HKSTP). It is a spin-off from the Centre for Virology, Vaccinology, and Therapeutics (CVVT) Limited, established in collaboration with a group of organoid scientists at the University of Hong Kong. BiomOrgan is proud to be the first company in the Asia-Pacific region to develop and commercialize a world-leading respiratory organoid platform.

We specialize in delivering the cutting-edge respiratory organoid system designed for biomedical research, disease modeling, drug screening, and evaluating the efficacy of therapeutics.

Empowered by our proprietary organoid technology and highly efficient organoid culture products, BiomOrgan enables academic, pharmaceutical, and biotech partners to accelerate innovation in biomedical research and drug development.

Our Mission is to harness the immense potential of organoid technology to address diverse biomedical and pharmaceutical challenges, including disease modelling, drug screening, viral surveillance, and personalized medicine.